Trial Profile
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis; Ischaemic heart disorders
- Focus Adverse reactions
- Acronyms XIENCE PRIME SV PMS
- Sponsors Abbott Laboratories; Abbott Vascular
- 12 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2021.
- 06 Aug 2015 New trial record